Ganti, Ketaki http://orcid.org/0000-0002-9687-3505
Bagga, Anish http://orcid.org/0000-0002-1355-7452
Carnaccini, Silvia http://orcid.org/0000-0002-1656-4068
Ferreri, Lucas M.
Geiger, Ginger http://orcid.org/0000-0002-4927-8084
Joaquin Caceres, C. http://orcid.org/0000-0001-8508-6592
Seibert, Brittany
Li, Yonghai
Wang, Liping
Kwon, Taeyong
Li, Yuhao http://orcid.org/0000-0003-2413-0937
Morozov, Igor http://orcid.org/0000-0002-9343-5446
Ma, Wenjun
Richt, Juergen A. http://orcid.org/0000-0001-7308-5672
Perez, Daniel R. http://orcid.org/0000-0002-6569-5689
Koelle, Katia http://orcid.org/0000-0002-0254-6141
Lowen, Anice C. http://orcid.org/0000-0002-9829-112X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (AI127799)
NIH/NIAID Centers of Excellence in Influenza Research and Response
Article History
Received: 18 February 2022
Accepted: 31 October 2022
First Online: 11 November 2022
Competing interests
: The JAR laboratory received support from Tonix Pharmaceuticals, Xing Technologies, and Zoetis, outside of the reported work. J.A.R. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections, owned by Kansas State University, KS. The remaining authors declare no competing interests.